Conflict of Interest: None.
A Review of Needle-Free Sumatriptan Injection for Rapid Control of Migraine
Version of Record online: 11 SEP 2013
© 2013 American Headache Society
Headache: The Journal of Head and Face Pain
Special Issue: New Delivery Systems
Volume 53, Issue Supplement S2, pages 21–33, September 2013
How to Cite
Rothrock, J. F., Freitag, F. G., Farr, S. J. and Smith, E. F. (2013), A Review of Needle-Free Sumatriptan Injection for Rapid Control of Migraine. Headache: The Journal of Head and Face Pain, 53: 21–33. doi: 10.1111/head.12183
- Issue online: 11 SEP 2013
- Version of Record online: 11 SEP 2013
- Manuscript Accepted: 26 APR 2013
- Medical Leverage
- Zogenix, Inc.
The treatment of migraine was transformed in 1992 with the introduction of the first triptan-based therapy, subcutaneous (SC) sumatriptan. SC sumatriptan has high efficacy and a rapid onset of action compared with other available triptans and formulations presumably because of its short Tmax, high Cmax, and avoidance of enteral absorption. Because of these characteristics, SC sumatriptan is still considered the most reliably and rapidly effective self-administered medication available for acute migraine. Even so, it is relatively little used possibly in part because of patient “needle-phobia.” The needle-free sumatriptan injection system (Sumavel DosePro) was developed to address this concern. Clinical trials have shown that the needle-free system is bioequivalent to needle-based injection systems, easy to use, and capable of providing rapid and effective symptom relief for many migraine episodes. Sumavel DosePro is an effective treatment for migraine and should be part of the therapeutic armamentarium, particularly in cases where a rapid onset of action is critical or where oral administration is problematic.